Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003131927 | SCV003812952 | uncertain significance | not provided | 2023-02-26 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV003131927 | SCV004562788 | likely benign | not provided | 2023-02-14 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003131927 | SCV005412524 | uncertain significance | not provided | 2023-10-03 | criteria provided, single submitter | clinical testing | PM2_moderate |
Ambry Genetics | RCV004961204 | SCV005474809 | uncertain significance | Inborn genetic diseases | 2024-11-10 | criteria provided, single submitter | clinical testing | The c.5393C>T (p.S1798F) alteration is located in exon 38 (coding exon 38) of the PIEZO1 gene. This alteration results from a C to T substitution at nucleotide position 5393, causing the serine (S) at amino acid position 1798 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003131927 | SCV005847507 | benign | not provided | 2024-11-22 | criteria provided, single submitter | clinical testing |